← back to search

Peter Schirmacher

Kliniken Essen-Mitte · DE
Area of research
Cancer Research · Epidemiology
Research interest
Research interests include Cancer Genomics and Diagnostics, Liver Disease Diagnosis and Treatment, Cholangiocarcinoma and Gallbladder Cancer Studies, and Lung Cancer Diagnosis and Treatment.
h-index
108
citations
62,774
works
1,414
NIH funding
primary concept
email

Recent publications

Artificial intelligence and the process of publishing scientific manuscripts.
2026cited by 0position: contributordoi
Multi-omics analysis to uncover the molecular basis of tumor budding in head and neck squamous cell carcinoma
npj Precision Oncology 2025cited by 6position: middledoi
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab – a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)
BMJ Open 2025cited by 5position: middledoi
Integrated in vivo combinatorial functional genomics and spatial transcriptomics of tumours to decode genotype-to-phenotype relationships
Nature Biomedical Engineering 2025cited by 4position: middledoi
Comprehensive genomic profiling requires a blended ecosystem of learning healthcare and clinical trials
British Journal of Cancer 2025cited by 2position: middledoi
High relevance of invasive fungal disease in chronic liver transplant failure: a comprehensive cross-sectional study.
2025cited by 1position: contributordoi
Supplementary Table S4 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025cited by 0position: contributordoi
Supplementary Figure S3 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025cited by 0position: contributordoi
Supplementary Appendix S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025cited by 0position: contributordoi
Supplementary Table S6 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025cited by 0position: contributordoi
Supplementary Table S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025cited by 0position: contributordoi
Supplementary Figures S2 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025cited by 0position: contributordoi
Supplementary Table S3 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025cited by 0position: contributordoi
Supplementary Table S2 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025cited by 0position: contributordoi
Data from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025cited by 0position: contributordoi
Supplementary Table S7 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025cited by 0position: contributordoi
Supplementary Figure S4 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025cited by 0position: contributordoi
Supplementary Table S5 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025cited by 0position: contributordoi
Supplementary Methods S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025cited by 0position: contributordoi
Supplementary Figures S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025cited by 0position: contributordoi
High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency–Associated Genomic Instability in Ovarian Cancer
JCO Precision Oncology 2024cited by 17position: middledoi
Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world study
European Journal of Cancer 2024cited by 11position: middledoi
Phosphatidylinositol 4-Kinase III Alpha Governs Cytoskeletal Organization for Invasiveness of Liver Cancer Cells
Gastroenterology 2024cited by 10position: middledoi
Dynamic YAP expression in the non-parenchymal liver cell compartment controls heterologous cell communication
Cellular and Molecular Life Sciences 2024cited by 9position: middledoi
Carbon ion radiotherapy of hepatocellular carcinoma provides excellent local control: The prospective phase I PROMETHEUS trial
JHEP Reports 2024cited by 7position: middledoi
N‐cadherin: A diagnostic marker to help discriminate primary liver carcinomas from extrahepatic carcinomas
International Journal of Cancer 2024cited by 7position: middledoi
Clinical Implementation of a High-Throughput Automated Comprehensive Genomic Profiling Test
Journal of Molecular Diagnostics 2024cited by 6position: middledoi
Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis.
2024cited by 3position: contributordoi
Molecular diagnostics of hepatobiliary and pancreatic neoplasias.
2024cited by 2position: contributordoi
Integrated combinatorial functional genomics and spatial transcriptomics of tumors decodes genotype to phenotype relationships
bioRxiv (Cold Spring Harbor Laboratory) 2024cited by 2position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Albrecht Stenzinger · Chirurgische Universitätsklinik Heidelberg84 papers (2012–2025)Volker Endris · Deutschen Konsortium für Translationale Krebsforschung52 papers (2015–2023)Wilko Weichert · German Cancer Research Center45 papers (2012–2025)Thomas Longerich · German Cancer Research Center39 papers (2012–2024)Daniel Kazdal · Heidelberg University39 papers (2016–2025)Jan Budczies · Incyte (United States)38 papers (2012–2025)Roland Penzel · Incyte (United States)37 papers (2012–2021)Kai Breuhahn · Heidelberg University35 papers (2012–2022)Anna‐Lena Volckmar · Heidelberg University34 papers (2016–2024)Martina Kirchner · Heidelberg University34 papers (2016–2024)Benjamin Goeppert · Kantonsspital Baselland32 papers (2012–2024)Olaf Neumann · Heidelberg University32 papers (2012–2024)Michael Allgäuer · Heidelberg University29 papers (2018–2024)Stéphanie Roessler · German Cancer Research Center28 papers (2013–2023)Stefan Fröhling · German Cancer Research Center26 papers (2016–2024)Arne Warth · Heidelberg University24 papers (2012–2020)Jonas Leichsenring · University Hospital Heidelberg23 papers (2016–2021)Marcus Renner · German Cancer Research Center21 papers (2012–2021)Wilfried Roth · Johannes Gutenberg University Mainz21 papers (2013–2024)Arianeb Mehrabi · High Throughput Biology (United States)20 papers (2013–2024)